Drugs / bevenopran
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02508740 | Sep → Dec 2013 | impaired renal function disease | Merck & Co., Inc. | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01275755 | Jan → Jul 2011 | constipation disorder | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01207427 | Oct 2010 → Apr 2011 | opioid-induced constipation | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT01901341 | Jul 2013 → Feb 2014 | opioid-induced constipation | Merck & Co., Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01901302 | May 2013 → Feb 2014 | opioid-induced constipation | Merck & Co., Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01901328 | Apr 2013 → Feb 2014 | opioid-induced constipation | Merck & Co., Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01696643 | Oct 2012 → Jul 2014 | opioid-induced constipation | Merck & Co., Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bevenopran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02508740 ↗ |
| Known as | ADL5945 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01207427 ↗ |
| Known as | CB-5945 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01696643 ↗ |
| Action | Inhibit | “Mu opioid receptor antagonist” CHEMBL3039511 ↗1“ADL5945, a MOR antagonist” NCT01207427 ↗ |
| Modality | Small molecule | — CHEMBL3039511 ↗ |
| Route | Oral | “one 0.1-milligrams (mg) ADL5945 capsule orally BID for 4 weeks” NCT01207427 ↗ |
| Target | OPRM1 | “Mu opioid receptor antagonist” CHEMBL3039511 ↗ |